Quanta Therapeutics is a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers using unique chemistry that targets multiple conformations of KRAS. Its allosteric approach aims to expand the scope of treatable KRAS-mutant cancers while evading known mechanisms of resistance. Lead programs include two chemically distinct allosteric KRAS inhibitors—QTX3034 (a multi-KRAS inhibitor) and QTX3046 (a G12D-selective inhibitor)—which showed favorable preclinical profiles at the AACR Annual Meeting, including potent anti-tumor activity, oral bioavailability, and brain penetration. Those programs are in IND-enabling studies to support anticipated clinical trial initiation in KRAS-driven solid tumor indications in 2024. Quanta also operates a RAF1 discovery program using direct allosteric modulation of the RAS-RAF1 membrane signaling complex; oral small-molecule leads from this program have shown in vivo proof-of-concept activity. The company has raised over $142 million since inception and intends to use the new proceeds to advance its pipeline toward clinical proof-of-concept. Quanta Therapeutics is a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancers. The company applies a platform that uses Second Harmonic Generation (SHG) optical technology to identify modulators of membrane-protein-complex conformation and detect functional protein states in real time. Its lead approach targets the active conformation of RAS across mutant forms with the aim of circumventing resistance mechanisms seen with first-generation KRAS inhibitors and producing novel small-molecule precision medicines. Founded in 2018 by Sofinnova Investments with co-founder Frank McCormick, Quanta has advanced programs against RAF1 and KRAS toward clinical candidate selection and IND filing. The company announced it closed an oversubscribed $60 million Series C and had previously raised $32 million while in stealth. Proceeds will be used to advance its RAF1 and KRAS programs through candidate selection, IND filing, and initial proof-of-concept.

Total raised

$111M

Funding rounds

2

Latest round

Series D

Latest activity

Jun 2023